Exelixis, Inc. (EXEL:NASDAQ) closed at $62.56 on October 19, 2026, up 0.52% on the day. The stock trades 1.3% below its 52-week high of $63.39 and 85.3% above its 52-week low of $33.76. Over the past year, it gained 58.5%. Exelixis, Inc. is part of the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| +4.03% | +6.39% | +12.07% | +42.70% | +58.55% |
In 252 trading sessions since October 16, 2025, EXEL closed higher on 131 days (52%). Its best day was May 6, 2026 (+9.64%) and its worst was October 20, 2025 (-12.00%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol...
Find more stocks like EXEL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.